Arbutus Total Operating Expenses vs Cost Of Revenue Analysis

ABUS Stock

USD 3.30 0.03 0.90%

Arbutus Biopharma financial indicator trend analysis is way more than just evaluating Arbutus Biopharma Corp prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Arbutus Biopharma Corp is a good investment. Please check the relationship between Arbutus Biopharma Total Operating Expenses and its Cost Of Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arbutus Biopharma Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

Total Operating Expenses vs Cost Of Revenue

Total Operating Expenses vs Cost Of Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Arbutus Biopharma Corp Total Operating Expenses account and Cost Of Revenue. At this time, the significance of the direction appears to have strong relationship.

The correlation between Arbutus Biopharma's Total Operating Expenses and Cost Of Revenue is 0.61. Overlapping area represents the amount of variation of Total Operating Expenses that can explain the historical movement of Cost Of Revenue in the same time period over historical financial statements of Arbutus Biopharma Corp, assuming nothing else is changed. The correlation between historical values of Arbutus Biopharma's Total Operating Expenses and Cost Of Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Operating Expenses of Arbutus Biopharma Corp are associated (or correlated) with its Cost Of Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cost Of Revenue has no effect on the direction of Total Operating Expenses i.e., Arbutus Biopharma's Total Operating Expenses and Cost Of Revenue go up and down completely randomly.

Correlation Coefficient

0.61

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Cost Of Revenue

Cost of Revenue is found on Arbutus Biopharma Corp income statement and represents the costs associated with goods and services Arbutus Biopharma provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Most indicators from Arbutus Biopharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Arbutus Biopharma Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arbutus Biopharma Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

At this time, Arbutus Biopharma's Selling General Administrative is comparatively stable compared to the past year. Issuance Of Capital Stock is likely to gain to about 47 M in 2025, whereas Sales General And Administrative To Revenue is likely to drop 1.06 in 2025.

Arbutus Biopharma fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Short Long Term Debt Total	Short Term Debt	Other Liab	Net Tangible Assets
Total Assets		-0.11	0.05	1.0	0.13	-0.72	-0.04	0.76	0.96	0.39	0.73	-0.09	0.31	0.07	0.1	0.96	-0.1	0.26	0.97	-0.01	0.72	-0.22	0.2	0.64	0.97	0.9
Other Current Liab	-0.11		0.73	-0.12	0.03	0.1	-0.49	-0.11	-0.25	-0.28	0.3	0.22	0.4	0.51	0.42	-0.25	0.34	0.06	-0.08	0.13	0.31	0.03	-0.37	-0.4	-0.2	-0.03
Total Current Liabilities	0.05	0.73		0.03	0.05	0.15	-0.63	-0.06	-0.13	-0.32	0.41	0.28	0.71	0.85	0.71	-0.03	0.34	0.24	0.14	0.58	0.42	-0.1	-0.08	-0.17	0.01	0.25
Total Stockholder Equity	1.0	-0.12	0.03		0.14	-0.74	-0.03	0.77	0.96	0.43	0.73	-0.09	0.3	0.05	0.08	0.95	-0.09	0.27	0.95	-0.02	0.72	-0.23	0.19	0.62	0.95	0.9
Property Plant And Equipment Net	0.13	0.03	0.05	0.14		0.15	-0.68	-0.11	-0.01	0.05	0.47	-0.27	0.56	0.31	0.58	0.05	0.41	0.29	0.11	0.52	0.47	-0.18	-0.48	0.02	0.02	-0.12
Net Debt	-0.72	0.1	0.15	-0.74	0.15		-0.2	-0.99	-0.7	-0.27	-0.53	-0.06	0.01	0.2	0.38	-0.69	-0.03	-0.22	-0.64	0.36	-0.52	0.24	-0.24	-0.41	-0.69	-0.64
Retained Earnings	-0.04	-0.49	-0.63	-0.03	-0.68	-0.2		0.12	0.19	0.41	-0.55	-0.06	-0.92	-0.85	-0.83	0.07	-0.73	-0.28	-0.07	-0.8	-0.56	0.09	0.53	0.29	0.04	-0.01
Cash	0.76	-0.11	-0.06	0.77	-0.11	-0.99	0.12		0.72	0.25	0.58	0.04	0.11	-0.09	-0.28	0.73	0.09	0.27	0.69	-0.23	0.57	-0.26	0.26	0.45	0.73	0.71
Non Current Assets Total	0.96	-0.25	-0.13	0.96	-0.01	-0.7	0.19	0.72		0.43	0.52	-0.12	0.08	-0.13	-0.11	0.97	-0.31	0.13	0.93	-0.17	0.51	-0.12	0.29	0.67	0.96	0.87
Non Currrent Assets Other	0.39	-0.28	-0.32	0.43	0.05	-0.27	0.41	0.25	0.43		0.2	-0.35	-0.28	-0.45	-0.1	0.34	-0.44	0.2	0.26	-0.3	0.19	-0.28	0.3	0.48	0.27	0.29
Cash And Short Term Investments	0.73	0.3	0.41	0.73	0.47	-0.53	-0.55	0.58	0.52	0.2		0.0	0.68	0.45	0.52	0.61	0.39	0.5	0.72	0.31	1.0	-0.38	-0.08	0.36	0.62	0.64
Net Receivables	-0.09	0.22	0.28	-0.09	-0.27	-0.06	-0.06	0.04	-0.12	-0.35	0.0		0.05	0.16	-0.03	-0.17	0.2	-0.02	-0.07	0.05	0.02	0.04	0.15	-0.21	-0.09	-0.08
Common Stock Total Equity	0.31	0.4	0.71	0.3	0.56	0.01	-0.92	0.11	0.08	-0.28	0.68	0.05		0.92	0.85	0.2	0.66	0.43	0.33	0.83	0.69	-0.24	-0.39	-0.08	0.23	0.34
Common Stock Shares Outstanding	0.07	0.51	0.85	0.05	0.31	0.2	-0.85	-0.09	-0.13	-0.45	0.45	0.16	0.92		0.82	-0.02	0.61	0.27	0.13	0.87	0.46	-0.09	-0.34	-0.29	0.04	0.23
Short Term Investments	0.1	0.42	0.71	0.08	0.58	0.38	-0.83	-0.28	-0.11	-0.1	0.52	-0.03	0.85	0.82		0.01	0.47	0.36	0.15	0.8	0.53	-0.2	-0.33	-0.08	0.01	0.13
Non Current Liabilities Total	0.96	-0.25	-0.03	0.95	0.05	-0.69	0.07	0.73	0.97	0.34	0.61	-0.17	0.2	-0.02	0.01		-0.23	0.2	0.97	-0.08	0.59	-0.17	0.3	0.71	0.99	0.87
Other Current Assets	-0.1	0.34	0.34	-0.09	0.41	-0.03	-0.73	0.09	-0.31	-0.44	0.39	0.2	0.66	0.61	0.47	-0.23		0.21	-0.15	0.53	0.41	-0.08	-0.43	-0.34	-0.21	-0.08
Other Stockholder Equity	0.26	0.06	0.24	0.27	0.29	-0.22	-0.28	0.27	0.13	0.2	0.5	-0.02	0.43	0.27	0.36	0.2	0.21		0.23	0.26	0.5	-0.98	-0.28	0.21	0.19	0.21
Total Liab	0.97	-0.08	0.14	0.95	0.11	-0.64	-0.07	0.69	0.93	0.26	0.72	-0.07	0.33	0.13	0.15	0.97	-0.15	0.23		0.01	0.7	-0.17	0.25	0.66	0.97	0.89
Property Plant And Equipment Gross	-0.01	0.13	0.58	-0.02	0.52	0.36	-0.8	-0.23	-0.17	-0.3	0.31	0.05	0.83	0.87	0.8	-0.08	0.53	0.26	0.01		0.32	-0.1	-0.31	-0.24	-0.04	0.07
Total Current Assets	0.72	0.31	0.42	0.72	0.47	-0.52	-0.56	0.57	0.51	0.19	1.0	0.02	0.69	0.46	0.53	0.59	0.41	0.5	0.7	0.32		-0.38	-0.08	0.34	0.6	0.63
Common Stock	-0.22	0.03	-0.1	-0.23	-0.18	0.24	0.09	-0.26	-0.12	-0.28	-0.38	0.04	-0.24	-0.09	-0.2	-0.17	-0.08	-0.98	-0.17	-0.1	-0.38		0.21	-0.25	-0.15	-0.15
Short Long Term Debt Total	0.2	-0.37	-0.08	0.19	-0.48	-0.24	0.53	0.26	0.29	0.3	-0.08	0.15	-0.39	-0.34	-0.33	0.3	-0.43	-0.28	0.25	-0.31	-0.08	0.21		0.65	0.25	0.32
Short Term Debt	0.64	-0.4	-0.17	0.62	0.02	-0.41	0.29	0.45	0.67	0.48	0.36	-0.21	-0.08	-0.29	-0.08	0.71	-0.34	0.21	0.66	-0.24	0.34	-0.25	0.65		0.62	0.58
Other Liab	0.97	-0.2	0.01	0.95	0.02	-0.69	0.04	0.73	0.96	0.27	0.62	-0.09	0.23	0.04	0.01	0.99	-0.21	0.19	0.97	-0.04	0.6	-0.15	0.25	0.62		0.88
Net Tangible Assets	0.9	-0.03	0.25	0.9	-0.12	-0.64	-0.01	0.71	0.87	0.29	0.64	-0.08	0.34	0.23	0.13	0.87	-0.08	0.21	0.89	0.07	0.63	-0.15	0.32	0.58	0.88

Click cells to compare fundamentals

Arbutus Biopharma Account Relationship Matchups

Arbutus Biopharma fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	137.1M	204.5M	195.4M	144.4M	166.1M	124.4M
Other Current Liab	5.8M	7.3M	20.5M	7.0M	8.1M	4.7M
Total Current Liabilities	9.5M	11.2M	32.9M	22.5M	25.9M	27.2M
Total Stockholder Equity	102.0M	169.4M	136.9M	106.0M	121.9M	93.5M
Property Plant And Equipment Net	9.3M	8.1M	6.8M	6.1M	7.0M	4.8M
Net Debt	(49.3M)	(106.7M)	(28.6M)	(17.6M)	(15.8M)	(16.6M)
Retained Earnings	(1.0B)	(1.1B)	(1.2B)	(1.3B)	(1.1B)	(1.1B)
Cash	52.3M	109.3M	30.8M	26.3M	30.2M	39.9M
Non Current Assets Total	9.4M	43.8M	44.3M	12.4M	14.2M	13.5M
Non Currrent Assets Other	293K	44K	61K	103K	92.7K	88.1K
Cash And Short Term Investments	123.3M	155.3M	146.9M	126.0M	144.9M	73.6M
Net Receivables	1.3M	899K	1.4M	1.8M	2.0M	1.3M
Common Stock Total Equity	898.5M	985.9M	1.3B	1.3B	1.5B	1.6B
Common Stock Shares Outstanding	75.8M	106.2M	150.9M	166.0M	190.9M	200.4M
Short Term Investments	71.0M	46.0M	116.1M	99.7M	114.7M	120.4M
Liabilities And Stockholders Equity	137.1M	204.5M	195.4M	144.4M	166.1M	124.4M
Non Current Liabilities Total	25.6M	23.8M	25.7M	15.9M	18.3M	25.0M
Other Current Assets	6.2M	8.9M	2.9M	4.2M	4.9M	5.1M
Other Stockholder Equity	60.8M	65.5M	72.4M	81.3M	93.5M	98.1M
Total Liab	35.1M	35.0M	58.6M	38.4M	44.1M	31.0M
Property Plant And Equipment Gross	9.3M	8.1M	6.8M	18.0M	20.7M	21.7M
Total Current Assets	127.7M	160.7M	151.1M	132.0M	151.8M	76.6M
Common Stock	985.9M	1.3B	1.3B	1.3B	1.6B	1.4B
Short Long Term Debt Total	3.0M	2.6M	2.2M	8.7M	10.0M	10.5M
Short Term Debt	780K	766K	744K	425K	488.8K	464.3K
Other Liab	21.9M	23.0M	21.6M	23.9M	27.5M	18.6M
Net Tangible Assets	(64.5M)	(47.4M)	169.4M	136.9M	157.4M	165.2M
Accounts Payable	3.0M	3.2M	3.5M	3.2M	3.7M	2.5M
Other Assets	44K	61K	103K	1.0	0.9	0.86
Retained Earnings Total Equity	(970.1M)	(1.0B)	(1.1B)	(1.2B)	(1.1B)	(1.0B)
Accumulated Other Comprehensive Income	(48.2M)	(48.3M)	(50.5M)	(48.4M)	(43.6M)	(41.4M)
Property Plant Equipment	8.7M	6.9M	6.0M	5.1M	5.8M	4.5M
Current Deferred Revenue	5.9M	7.6M	16.5M	11.8M	13.6M	14.2M
Capital Surpluse	55.2M	60.8M	65.5M	72.4M	83.3M	53.5M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Arbutus Stock Analysis

When running Arbutus Biopharma's price analysis, check to measure Arbutus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arbutus Biopharma is operating at the current time. Most of Arbutus Biopharma's value examination focuses on studying past and present price action to predict the probability of Arbutus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arbutus Biopharma's price. Additionally, you may evaluate how the addition of Arbutus Biopharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC